Blockchain Registration Transaction Record

VERAXA Appoints Raju Willener as CFO to Drive Oncology Pipeline

VERAXA Biotech names Raju Willener as CFO, bringing 30+ years of capital markets expertise to advance its BiTAC oncology pipeline and novel cancer therapies.

The appointment of Raju Willener as CFO brings decades of capital markets expertise to VERAXA at a critical juncture. As the company advances its BiTAC platform, including promising antibody-drug conjugates and T-cell engagers, strong financial leadership is essential to secure funding, manage partnerships, and navigate regulatory pathways. For patients and investors, this could mean faster development of innovative cancer therapies that address unmet needs. Willener’s experience in international finance and corporate development will help VERAXA scale efficiently, potentially accelerating the delivery of next-generation treatments. In the competitive biotech landscape, such strategic hires often signal a company’s readiness to transition from research to commercialization, making this news a positive indicator for stakeholders.